PD-1 is a type I immune inhibitory transmembrane receptor of the CD28 family that modulates the activity of T cells in peripheral tissues [1] . It is expressed in T cells, B cells, monocytes, natural killer cells and many tumor-infiltrating lymphocytes [2] . Binding of PD-1 to its ligands PD-L1 and PD-L2 reduces T-cell activity [3] . Thereby, under normal conditions, the interaction of PD-1 with PD-L1 or PD-L2 prevents excessive lymphocyte activation and maintains immune tolerance to self-antigens by negatively regulating the immune response [3] . However, PD-L1 is often overexpressed in different tumors including lymphoma, melanoma, nonsmall-cell lung cancer and other types of cancer [2] . As a result, tumor cells attenuate T-cell signaling to evade immune surveillance [4] . Blocking PD-1/PD-L1 interaction has been shown to restore T-cell activation and antitumor response, providing the rationale for therapeutic intervention using PD-1/PD-L1 as target [5] . Currently two monoclonal antibody-based drugs targeting PD-1 are in clinical trials. One is nivolumab or Opdivo from Bristol-Myers Squibb. The other is pembrolizumab or Keytruda, a therapeutic IgG4 antibody developed by Merck.
Crystal structures of mouse PD-1 (mPD-1) in complex with human PD-L1 (hPD-L1), mPD-1 complexed with mouse PD-L2 (mPD-L2) and human PD-1 (hPD-1) in complex with hPD-L1 have revealed the structural basis of PD-1's interaction with its ligands [6-8]. Crystal structure of the full-length pembrolizumab was also reported recently [9] . However, how pembrolizumab specifically recognizes hPD-1 is still unknown. Herein, we report the crystal structure of pembrolizumab Fab (antigen-binding fragment) in complex with hPD-1, revealing the molecular basis for the blockade of hPD-1/hPD-L1 interaction by pembrolizumab.
Crystal structure of the hPD-1/pembrolizumab Fab complex (hPD-1/Fab) was determined at a resolution of 2.9 Å (Supplementary information, Table S1 ). hPD-1 and pembrolizumab Fab form a 1:1 complex ( Figure 1A) , consistent with the stoichiometry determined by previous results [10] . hPD-1 is made up of a canonical β-sandwich immunoglobulin variable (IgV) topology with a disulfide bond between Cys 54 and Cys 123 . Structural comparison of hPD-1 with apo-hPD-1 (PDB: 3RRQ) and hPD-1 structure extracted from the hPD-1/hPD-L1 complex (PDB: 4ZQK) shows that hPD-1 in the hPD-1/Fab complex resembles the conformation observed in the hPD-1/ hPD-L1 complex. The pembrolizumab Fab in the complex exhibits a canonical β-sandwich immunoglobulin fold closely resembling the full-length pembrolizumab antibody (Supplementary information, Figure S1) [9].
The interaction of PD-1 with pembrolizumab Fab buries ~1 774 Å 2 surface area, and the hPD-1/Fab interface can be divided into two sub-interfaces. Sub-interface I mainly encompasses the C′D loop of hPD-1 and pembrolizumab Fab's complementary determining regions (CDRs) L1, L3, H2 and four β-strands of framework region (FR), which interact through polar, charged and hydrophobic contacts ( Figure 1B) . The most notable feature of this sub-interface is that the C′D loop of hPD-1 protrudes into a groove formed by the CDRs and FR of pembrolizumab Fab. Specifically, Asp 85 of hPD-1 establishes a salt bridge with Arg H99 of FR (hereafter residues of the Fab light chain and heavy chain are designated by superscript chain identifiers L and H, respectively). The side chain of Ser 87 forms hydrogen bond with Arg H99 of FR. Interestingly, two arginines Arg 86 and Arg L96 are involved in a T-shaped stacking interaction. The backbone of C′D loop residues Glu 84 , Ser 87 , Gln 88 and Gly 90 are held in place by hydrogen bonds with side chains of Tyr L36 , Tyr H35 , Asn H59 and Thr H58 , respectively. Furthermore, Pro 89 of hPD-1 inserts into a cavity formed by side chains of Tyr H33 , Tyr H35 , Asn H52 and Asn H59 of β-stands 1, 2 and 3, and the main chains of Gly H50 , Ile H51 , Gly H57 and Thr H58 of β-stands 1 and 2.
Sub-interface II is dominated by hydrophilic interactions and brings together residues in the C, C′ and F strands of hPD-1 and CDRs L1 and H3 of Fab ( Figure  1C The extensive interactions at the hPD-1/Fab interface are consistent with the high binding affinity of pembrolizumab to the hPD-1, with an apparent disassociation constant (K D ) of 27 pM. In the previously published hPD-1 structures (PDB: 3RRQ and 4ZQK), the C′D loop of hPD-1 is disordered and is assumed to be highly flexible [8, 10]. However, the C′D loop of hPD-1 in our hPD-1/Fab complex structure is well ordered, as evidenced by its well-defined electron density, and it contributes to sub-interface I with Fab. Although mPD-1 and hPD-1 share 60% sequence identity and an IgV topology, hPD-1 lacks the additional C″ strand observed in mPD-1 ( Figure 1D ). Moreover, Asp 85 and Arg 86 in hPD-1 are substituted by Gly 85 and Leu 86 in mPD-1, respectively. Mutations in hPD-1, D85G and R86L show significant differences in their binding affinities with pembrolizumab. D85G abolishes hPD-1 binding to pembrolizumab as determined by ELISA ( Figure 1E ). This can be attributed to the disruption of the salt bridge with Arg H99 of Fab, which can conceivably impair the PD-1/Fab complex assembly. However, R86L did not affect the binding affinity between hPD-1 and pembrolizumab. These results are consistent with earlier data showing that pembrolizumab displays low binding affinity toward mPD-1 (Patent: WC500190992).
Structural superposition of the hPD-1/pembrolizumab Fab complex and the hPD-1/hPD-L1 complex shows that pembrolizumab Fab and hPD-L1 interact with hPD-1 through overlapping surface regions, suggesting that pembrolizumab and hPD-L1 can exclude each other from binding to hPD-1 ( Figure 1F ). Although the C′D loop in the sub-interface I contributes predominantly to the binding affinity of permbrolizumab, the C′D loop is disordered in the hPD-1/hPD-L1 complex, suggesting that it is not important for the hPD-1/hPD-L1 interaction. Consistent with this observation, the overlapping regions are mainly located in the sub-interface II, where the antigen-binding site of permbrolizumab Fab largely overlaps with the regions of hPD-L1 that interact with hPD-1.
A second ligand for PD-1 is PD-L2, which shares 34% sequence identity with PD-L1 and exhibits 3-fold higher binding affinity for PD-1 [7] . Given that mPD-L2 and hPD-L2 share a sequence identity of 72%, we modeled the hPD-1/hPD-L2 complex based on the structures of hPD-1/hPD-L1 and mPD-1/mPD-L2. Structural superposition of hPD-1/pembrolizumab Fab complex and modeled hPD-1/hPD-L2 complex suggest that pembrolizumab Fab would also compete with hPD-L2 for binding to hPD-1 (Supplementary information, Figure S2 ) through overlapping regions similar to those observed between hPD-1/pembrolizumab Fab and hPD-1/hPD-L1. Taken together, these observations suggest a mechanism by which pembrolizumab outcompetes PD-L1 or PD-L2 for binding to hPD-1.
In summary, we have reported the crystal structure of the pembrolizumab Fab in complex with the ectodomain of hPD-1. Pembrolizumab Fab uses its CDRs and FR to interact with the C′D loop of hPD-1, which appears unstructured in previously published reports. The epitope consists of several discontinuous segments of hPD-1, which overlap with the region that interacts with hPD-L1 or hPD-L2, suggesting a mechanism by which pembrolizumab prevents the binding of hPD-L1 or hPD-L2 to hPD-1. These results have implications for the design and improvement of mAb drugs targeting hPD-1.
The atomic coordinates and structure factors for hPD-1/pembrolizumab Fab complex structure have been deposited into Protein Data Bank under the accession code of 5JXE. Additional details of the methods are described in Supplementary information, Data S1.
